X4 PHARMACEUTICALS, INC Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- X4 PHARMACEUTICALS, INC payments for repurchase of common stock for the quarter ending 2023-03-31 was $443.00K.
- X4 PHARMACEUTICALS, INC payments for repurchase of common stock for the quarter ending 2022-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC payments for repurchase of common stock for the quarter ending 2021-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC payments for repurchase of common stock for the quarter ending 2020-12-31 was $0.00.
- X4 PHARMACEUTICALS, INC payments for repurchase of common stock for fiscal 2023 was $0.00.
- X4 PHARMACEUTICALS, INC payments for repurchase of common stock for fiscal 2022 was $0.00, a 100.00% decline from fiscal 2021.
- X4 PHARMACEUTICALS, INC payments for repurchase of common stock for fiscal 2021 was $2.00M.
- X4 PHARMACEUTICALS, INC payments for repurchase of common stock for fiscal 2020 was $0.00.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-03-21 | |
| 2023-03-31 | $443.00K 10-Q · filed 2023-05-04 | |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $0.00 10-K · filed 2024-03-21 |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | $2.00M 10-K · filed 2024-03-21 |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-21 | $0.00 10-K · filed 2023-03-21 |
| 2019-12-31 | $0.00 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |